Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

[Treatment and course of a man with systemic sclerosis before and after hematopoetic blood stem cell transplantation].

Blank N, Lorenz HM.

Dtsch Med Wochenschr. 2013 Sep;138(37):1824-7. doi: 10.1055/s-0033-1349503. Epub 2013 Sep 4. German.

PMID:
24006162
2.

Long-term follow-up results after autologous haematopoietic stem cell transplantation for severe systemic sclerosis.

Vonk MC, Marjanovic Z, van den Hoogen FH, Zohar S, Schattenberg AV, Fibbe WE, Larghero J, Gluckman E, Preijers FW, van Dijk AP, Bax JJ, Roblot P, van Riel PL, van Laar JM, Farge D.

Ann Rheum Dis. 2008 Jan;67(1):98-104. Epub 2007 May 25. Erratum in: Ann Rheum Dis. 2008 Feb;67(2):280.

PMID:
17526554
3.

Autologous stem-cell transplantation in progressing amyloidosis is associated with severe transplant-related toxicity.

Worel N, Schulenburg A, Mitterbauer M, Keil F, Rabitsch W, Kalhs P, Gisslinger H, Raderer M, Geissler K, Höcker P, Zielinski CC, Oberbauer R, Greinix HT.

Wien Klin Wochenschr. 2006 Feb;118(1-2):49-53.

PMID:
16489526
4.

Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin disease.

Binks M, Passweg JR, Furst D, McSweeney P, Sullivan K, Besenthal C, Finke J, Peter HH, van Laar J, Breedveld FC, Fibbe WE, Farge D, Gluckman E, Locatelli F, Martini A, van den Hoogen F, van de Putte L, Schattenberg AV, Arnold R, Bacon PA, Emery P, Espigado I, Hertenstein B, Hiepe F, Kashyap A, Kötter I, Marmont A, Martinez A, Pascual MJ, Gratwohl A, Prentice HG, Black C, Tyndall A.

Ann Rheum Dis. 2001 Jun;60(6):577-84.

5.

Autologous bone marrow transplantation in the treatment of refractory systemic sclerosis: early results from a French multicentre phase I-II study.

Farge D, Marolleau JP, Zohar S, Marjanovic Z, Cabane J, Mounier N, Hachulla E, Philippe P, Sibilia J, Rabian C, Chevret S, Gluckman E; Intensification et Autogreffe dans les Maladies Auto Immunes Resistantes (ISAMAIR) Study Group..

Br J Haematol. 2002 Dec;119(3):726-39.

PMID:
12437652
6.

Safety of autologous hematopoietic stem cell transplantation in patients with multiple myeloma and chronic renal failure.

Tosi P, Zamagni E, Ronconi S, Benni M, Motta MR, Rizzi S, Tura S, Cavo M.

Leukemia. 2000 Jul;14(7):1310-3.

PMID:
10914557
7.

High-dose melphalan with G-CSF-stimulated whole blood rescue followed by stem cell harvesting and busulphan/cyclophosphamide with autologous stem cell transplantation in multiple myeloma.

Huijgens PC, Dekker-Van Roessel HM, Jonkhoff AR, Admiraal GC, Zweegman S, Schuurhuis GJ, Ossenkoppele GJ.

Bone Marrow Transplant. 2001 May;27(9):925-31.

10.
11.

Optimization of autologous stem cell transplantation for systemic sclerosis -- a single-center longterm experience in 26 patients with severe organ manifestations.

Henes JC, Schmalzing M, Vogel W, Riemekasten G, Fend F, Kanz L, Koetter I.

J Rheumatol. 2012 Feb;39(2):269-75. doi: 10.3899/jrheum.110868. Epub 2012 Jan 15.

PMID:
22247352
12.

Mobilization and selection of peripheral blood hematopoietic progenitors in children with systemic sclerosis.

Locatelli F, Perotti C, Torretta L, Maccario R, Montagna D, Ravelli A, Giorgiani G, De Benedetti F, Giraldi E, Magnani ML, De Stefano P, Martini A.

Haematologica. 1999 Sep;84(9):839-43.

13.

Analysis of immune reconstitution after autologous CD34+ stem/progenitor cell transplantation for systemic sclerosis: predominant reconstitution of Th1 CD4+ T cells.

Tsukamoto H, Nagafuji K, Horiuchi T, Mitoma H, Niiro H, Arinobu Y, Inoue Y, To K, Miyamoto T, Iwasaki H, Teshima T, Harada M, Akashi K.

Rheumatology (Oxford). 2011 May;50(5):944-52. doi: 10.1093/rheumatology/keq414. Epub 2010 Dec 20.

PMID:
21172925
14.

Successful autologous hematopoietic stem cell transplantations for severe multiple sclerosis with fludarabine and cyclophosphamide conditioning.

Loh SM, Ratnagopal P, Tan HC, Goh YT, Koh BC, Koh LP, Linn YC, Hwang WY.

Int J Hematol. 2006 May;83(4):368-9. No abstract available.

PMID:
16757442
15.

Veno-occlusive disease of the liver after high-dose cytoreductive therapy with busulfan and melphalan for autologous blood stem cell transplantation in multiple myeloma patients.

Carreras E, Rosiñol L, Terol MJ, Alegre A, de Arriba F, García-Laraña J, Bello JL, García R, León A, Martínez R, Peñarrubia MJ, Poderós C, Ribas P, Ribera JM, San Miguel J, Bladé J, Lahuerta JJ; Spanish Myeloma Group/PETHEMA..

Biol Blood Marrow Transplant. 2007 Dec;13(12):1448-54.

16.

Stem cell transplantation in systemic sclerosis.

van Laar JM, Sullivan K.

Curr Opin Rheumatol. 2013 Nov;25(6):719-25. doi: 10.1097/01.bor.0000434669.32150.ac. Review.

PMID:
24047607
17.

Identification of prognostic factors for plerixafor-based hematopoietic stem cell mobilization.

Basak GW, Jaksic O, Koristek Z, Mikala G, Mayer J, Masszi T, Labar B, Wiktor-Jedrzejczak W; Central and Eastern European Leukemia Group (CELG)..

Am J Hematol. 2011 Jul;86(7):550-3. doi: 10.1002/ajh.22038. Epub 2011 Jun 14.

18.
19.

Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of multiple myeloma patients: positive selection and transplantation of enriched CD34+ cells to remove circulating tumor cells.

Lemoli RM, Fortuna A, Motta MR, Rizzi S, Giudice V, Nannetti A, Martinelli G, Cavo M, Amabile M, Mangianti S, Fogli M, Conte R, Tura S.

Blood. 1996 Feb 15;87(4):1625-34.

20.

Supplemental Content

Support Center